C12N 2770/20041
Use of virus, viral particle or viral elements as a vector
C12N2770/20041 (Use of virus, viral particle or viral elements as a vector) appears on 23 US grants and 71 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 71
- Assignees
- 64
- Inventors
- 224
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 2 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 3 |
| 2007 | 1 | 2 |
| 2008 | 2 | 0 |
| 2009 | 2 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 4 |
| 2023 | 4 | 22 |
| 2024 | 0 | 10 |
| 2025 | 2 | 6 |
| 2026 | 5 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/20043Viral genome or elements thereof as genetic vectorIndexing code18
- C12N 2770/20042Virus or viral particle as vehicleIndexing code3
- C12N 2770/20044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code3
- C12N 2770/20045Special targeting system for viral vectorsIndexing code0
Recent patents
- Modified gene vaccines against avian coronaviruses and methods of using the same21 Jul 2026US 12,685,766 B2Wisconsin Alumni Research Foundation
- Coronavirus pseudovirus packaging system, packaging method therefor, and application of coronavirus pseudovirus in evaluating disinfection efficacy14 Apr 2026US 12,600,988 B2Fantasia Biopharma (Zhejiang) Co. Ltd
- Single-chain coronavirus viral membrane protein complexes24 Mar 2026US 12,582,710 B2University of Houston System
- Methods for control of an infective disease with a vaccine24 Mar 2026US 12,583,890 B2Russellville Cardiology Consultants, P.A.
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof6 Aug 2026US 2026/0226462 A1Elixirgen Therapeutics, Inc.
- Method for constructing circular rna and vaccine against fipv21 May 2026US 2026/0137770 A1Beijing Syngentech Co., Ltd.
- Development of multi-antigen mrna vaccine against feline fipv21 May 2026US 2026/0137771 A1Beijing Syngentech Co., Ltd.
- Sars coronavirus 2 recombinant vectors expressing reporter genes, derived from gh clade sars coronavirus 2 of korean isolate, and the production method therefor12 Mar 2026US 2026/0071190 A1RpexBio, Inc.
- Enveloped virus like particles comrising sars-cov-2 s protein15 Jan 2026US 2026/0014249 A1National Research Council of Canada
Most cited
By later US patents
- Directional assembly of large viral genomes and chromosomes20US 6,593,111 B2The University of North Carolina at Chapel Hill · 2003
- Induce and enhance immune responses using recombinant replicon systems12US 11,083,786 B2Janssen Pharmaceuticals, Inc. · 2021
- Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines6US 7,041,300 B1Cyanamid Iberica, S.A. · 2006
- Canine coronavirus S gene and uses therefor5US 6,057,436 APfizer Inc. · 2000
- Canine coronavirus S gene and uses therefor5US 6,372,224 B1Pfizer Inc. · 2002